REGN.O
Latest Trade
288.12USDChange
--(--)Volume
--Today's Range
-
--52 Week Range
-
442.00As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 288.12 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 16.14 |
Today's High | -- |
Today's Low | -- |
52 Week High | 442.00 |
52 Week Low | 271.57 |
Shares Out (MIL) | 109.83 |
Market Cap (MIL) | 30,871.38 |
Forward P/E | 12.19 |
Dividend (Yield %) | -- |
FDA Approves Regeneron's Eylea Injection In Prefilled Syringe
Regeneron Pharmaceuticals Q2 Non-GAAP Earnings Per Share $6.02
Sanofi: Libtayo (Cemiplimab) Approved For Advanced Cutaneous Squamous Cell Carcinoma In EU
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Industry
Biotechnology & Drugs
Executive Leadership
P. Roy Vagelos
Chairman of the Board, Director
Leonard S. Schleifer
President, Chief Executive Officer, Director
Robert E. Landry
Chief Financial Officer, Executive Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Price To Earnings (TTM) | 16.43 |
|---|---|
Price To Sales (TTM) | 4.27 |
Price To Book (MRQ) | 3.22 |
Price To Cash Flow (TTM) | 14.14 |
Total Debt To Equity (MRQ) | 7.29 |
LT Debt To Equity (MRQ) | 7.29 |
Return on Investment (TTM) | 19.93 |
Return on Equity (TTM) | 17.31 |
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.
Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.
Regeneron Pharmaceuticals Inc <REGN.O> beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by double-digit sales growth of its blockbuster treatment Eylea in the United States.
Regeneron Pharmaceuticals Inc reported better-than-expected quarterly revenue on Tuesday, boosted by demand for its blockbuster eye drug, Eylea.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.
The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.
Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.
The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.
The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market...
Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.
A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.
A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.
Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.
Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.
Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.
Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.